A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT ID: NCT06595238
Last Updated: 2025-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
262 participants
INTERVENTIONAL
2024-10-01
2025-12-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A screening period of maximum 28 days
A treatment period of 36 weeks
A follow up period after last dose of study drug
This study will consist of 4 cohorts. Approximately 231 eligible participants will be randomized to AZD6234 or placebo
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Dose 1
AZD6234
IMP injected subcutaneously, once a week. Unit dose strength as per CSP
Arm 2
Dose 2
AZD6234
IMP injected subcutaneously, once a week. Unit dose strength as per CSP
Arm 3
Dose 3
AZD6234
IMP injected subcutaneously, once a week. Unit dose strength as per CSP
Arm 4
Placebo - Dose matched with each Experimental arm
Placebo comparator
Placebo matching IMP dose injected subcutaneously, once a week.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD6234
IMP injected subcutaneously, once a week. Unit dose strength as per CSP
Placebo comparator
Placebo matching IMP dose injected subcutaneously, once a week.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI of (a) ≥ 30 kg/m2, or (b) ≥ 27kg/m2 and have a current diagnosis of at least 1 weight-related comorbidities (treated or untreated)
* A stable body weight for 3 months prior to Screening (±5% body weight change)
Exclusion Criteria
* Has received prescription or non-prescription medication for weight loss within the last 3 months prior to Screening
* Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)
* History of type 1 diabetes mellitus or T2DM
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Mobile, Alabama, United States
Research Site
Phoenix, Arizona, United States
Research Site
Long Beach, California, United States
Research Site
Hialeah, Florida, United States
Research Site
Largo, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Woodstock, Georgia, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Lutherville-Timonium, Maryland, United States
Research Site
Gulfport, Mississippi, United States
Research Site
Ridgeland, Mississippi, United States
Research Site
Kansas City, Missouri, United States
Research Site
Omaha, Nebraska, United States
Research Site
Portsmouth, New Hampshire, United States
Research Site
Statesville, North Carolina, United States
Research Site
North Charleston, South Carolina, United States
Research Site
Knoxville, Tennessee, United States
Research Site
Austin, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Port Arthur, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Heidelberg, , Australia
Research Site
Maroochydore, , Australia
Research Site
Maroubra, , Australia
Research Site
Merewether, , Australia
Research Site
Hamilton, Ontario, Canada
Research Site
Sarnia, Ontario, Canada
Research Site
Stouffville, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Sherbrooke, Quebec, Canada
Research Site
Chūōku, , Japan
Research Site
Chūōku, , Japan
Research Site
Shinjuku-ku, , Japan
Research Site
Suita-shi, , Japan
Research Site
Hull, , United Kingdom
Research Site
Leicester, , United Kingdom
Research Site
Penarth, , United Kingdom
Research Site
Rotherham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-514000-13-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
D8750C00004
Identifier Type: -
Identifier Source: org_study_id